CORAL GABLES, Fla., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for the use of GABA aminotransferase inhibitors, including CPP-109 and CPP-115, in the treatment of Tourette Syndrome. Catalyst, one of the inventors, through a license agreement with the co-inventors' respective institutions, has exclusive worldwide rights to GABA aminotransferase inhibitors for this use.
